Author: lowes1

Posted on

Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine

Condition:   Bronchial Asthma
Interventions:   Drug: Ke Chuan Liu Wei Mixture;   Drug: Chuan Xiong Ping Chuan Mixture;   Drug: Xie Wu Capsule;   Drug: Dan Ma Jia Tablet;   Drug: Zhi Chuan Capsule;   Drug: Bu Shen Na Qi Granule;   Drug: Ke Chuan Liu Wei Mixture placebo;   Drug: Chuan Xiong Ping Chuan Mixture placebo;   Drug: Xie Wu Capsule placebo;   Drug: Dan Ma Jia Tablet placebo;   Drug: Zhi Chuan Capsule placebo;   Drug: Bu Shen Na Qi Granule placebo
Sponsor:   Shanghai University of Traditional Chinese Medicine
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

Th1/Th2 Immune Balance and Other T Helper Subsets in IgG4-Related Disease.

Related Articles

Th1/Th2 Immune Balance and Other T Helper Subsets in IgG4-Related Disease.

Curr Top Microbiol Immunol. 2016 Oct 16;

Authors: Moriyama M, Nakamura S

Abstract
IgG4-related disease (IgG4-RD) is a systemic disease characterized by elevated serum IgG4 levels and a strong infiltration of IgG4-positive plasma cells in various organs. IgG4-RD patients also frequently suffer from allergic diseases, including asthma and atopic dermatitis. It is well known that T helper type 2 (Th2) cells have an important role in the initiation of allergic diseases, and Th2 cytokines such as interleukin (IL)-4 and IL-13 promote class switching to IgG4. Therefore, IgG4-RD is considered to be a Th2-predominant disease. However, other Th subsets, including regulatory T cells and T follicular helper cells, have recently received increasing attention with regard to the pathogenesis of IgG4-RD. Exploring the interconnected network of Th subsets in IgG4-RD is a highly promising field of investigation. In this review, we focus on the localization and functions of individual Th subsets to clarify the involvement of these cells in the pathogenesis of IgG4-RD.

PMID: 27744510 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers.

Condition:   Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: Treatment A – AZD7594;   Drug: Treatment B – AZD7594;   Drug: Treatment C – AZD7594
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers.

Condition:   Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: Treatment A – AZD7594;   Drug: Treatment B – AZD7594;   Drug: Treatment C – AZD7594
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a Real-Life Clinical Assessment.

Related Articles

European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a Real-Life Clinical Assessment.

Allergy. 2016 Oct 8;:

Authors: Calderón MA, Vidal C, Rodríguez Del Río P, Just J, Pfaar O, Tabar AI, Sánchez-Machín I, Bubel P, Borja J, Eberle P, Reiber R, Bouvier M, Lepelliez A, Klimek L, Demoly P, EASSI Doctors’ Group

Abstract
BACKGROUND: Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (AIT) are scarce.
METHODS: A prospective, longitudinal, web-based survey of “real-life” respiratory allergen immunotherapy (AIT) clinical practice was conducted in France, Germany and Spain. SRs were recorded and coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and risk factors associated with SRs were identified.
RESULTS: A total of 4,316 patients (corresponding to 4,363 ongoing courses of AIT) were included. 109 SRs were recorded, and 90 patients (2.1%) presented at least one SR. Most of the SRs occurred in subcutaneous allergen immunotherapy (SCIT) (89%, n=97). The most frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough. Respiratory symptoms appeared before skin symptoms. Most SRs occurred during the up-dosing phase (75.8%) and were mild in severity (71.6%). Intramuscular adrenaline was administered in 17 SRs but only 65% of these were subsequently classified as anaphylaxis. Independent risk factors for SRs during SCIT were: the use of natural extracts (odds ratio (OR) [95% confidence interval (CI)]=2.74 [1.61-4.87]; p=0.001), the absence of symptomatic allergy medications (1.707 [1.008-2.892], p=0.047), asthma diagnosis (1.74 [1.05-2.88], p=0.03), sensitization to animal dander (1.93 [1.21-3.09]; p=0.006) or pollen (1.16 [1.03-1.30]; p=0.012), and cluster regimens (vs. rush) (4.18 [1.21-14.37]; p=0.023). A previous episode of anaphylaxis increased the risk for anaphylaxis in SCIT (OR [95%CI]=17.35 [1.91-157.28]; p=0.01).
CONCLUSION: AIT for respiratory allergy is safe, with a low number of SRs observed in real-life clinical practice. A personalized analysis of risk factors could be used to minimize SRs. This article is protected by copyright. All rights reserved.

PMID: 27718250 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

A 12-week, Randomized, Parallel-Group, Proof-of-Concept Study of Tulobuterol Patch and Salmeterol Inhaler as Add-on Therapy in Adult-Onset Mild-to-Moderate Asthma.

Related Articles

A 12-week, Randomized, Parallel-Group, Proof-of-Concept Study of Tulobuterol Patch and Salmeterol Inhaler as Add-on Therapy in Adult-Onset Mild-to-Moderate Asthma.

Clin Exp Pharmacol Physiol. 2016 Oct 8;:

Authors: Inoue H, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Tajiri T, Iwata T, Nagasaki T, Mishima M

Abstract
Patch formulation of tulobuterol has been used in asthma treatment as a long-acting ?2 -agonist (LABA) through sustained skin absorption. Its treatment efficacy, especially in small airways, remains poorly understood. The study aim was to investigate LABA add-on effects of tulobuterol patch (TP) and salmeterol inhaler (SA) on pulmonary function, asthma control, and health status. Patients who had adult-onset under-controlled asthma, despite taking inhaled corticosteroids, were enrolled in a randomized, open-label, parallel-group, proof-of-concept study of 12-week add-on treatment with TP (n = 16) or SA (n = 17). Spirometry, impulse oscillometry (IOS), exhaled nitric oxide levels, and clinical questionnaires of asthma control, health status (St. George’s Respiratory Questionnaire: SGRQ), and symptoms were evaluated every 4 weeks. Add-on treatment of SA significantly improved the spirometric indices of small airway obstruction (forced expiratory flow between 25% and 75% of FVC: FEF25-75 , and maximum expiratory flow at 25% of FVC: MEF25 ) and IOS indices of whole respiratory resistance (resistance at 5 Hz) as compared to TP. In intra-group comparisons, add-on treatment of TP improved the scores of the asthma control test and the total SGRQ, as well as the symptom and impact components of the SGRQ. SA add-on treatment improved FEV1 and IOS parameters of resistance at 20 Hz and reactance at 5 Hz. Neither of the treatments improved exhaled nitric oxide levels. In conclusion, add-on treatment of TP improved asthma control and health status, whereas SA improved pulmonary function measures associated with large and small airway involvement among patients with adult-onset mild-to-moderate asthma. This article is protected by copyright. All rights reserved.

PMID: 27718262 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Effect of compound Maqin decoction on TGF-?1/Smad proteins and IL-10 and IL-17 content in lung tissue of asthmatic rats.

Effect of compound Maqin decoction on TGF-?1/Smad proteins and IL-10 and IL-17 content in lung tissue of asthmatic rats.

Genet Mol Res. 2016 Sep 2;15(3):

Authors: Xie YH, Li XP, Xu ZX, Qian P, Li XL, Wang YQ

Abstract
In this research, compound Maqin decoction (CMD) has been shown to positively affect in airway inflammation of asthma models. We evaluated the effects of CMD on the expression of transforming growth factor (TGF)-?1/Smad proteins, interleukin (IL)-17, and IL-10 in lung tissue of asthmatic rats. Asthma was induced in a rat model using ovalbumin. After a 4-week treatment with CMD, rats were killed to evaluate the expression of TGF-?1 and Smad proteins in lung tissue. IL-10 and IL-17 levels in lung tissue homogenates were determined by ELISA. The expression of TGF-?1 and Smad3 protein increased, whereas expression of Smad7 protein decreased upon high-dose or low-dose treatment with CMD or by intervention with dexamethasone, compared to the control. There was a significant difference between treatment with a high dose CMD and the control treatment, but no significant difference was found between high-dose CMD treatment and dexamethasone intervention. The expression of TGF-?1 and Smad7 protein increased, whereas the expression of Smad3 protein decreased in the model group compared to other groups. In the CMD high-dose group, low-dose group, and dexamethasone intervention group, the IL-17 concentrations in lung tissue homogenates were decreased, while IL-10 levels were increased. Again, there was a significant difference between CMD high-dose and control treatment, but not between CMD high-dose treatment and dexamethasone intervention. Thus, positive effects of CMD against asthmatic airway remodeling may be due to its regulatory effect on TGF-?1, Smad3, and Smad7 protein levels and on cytokines such as IL-10 and IL-17.

PMID: 27706676 [PubMed – in process]

View full post on pubmed: asthma

Posted on

Lung Obstruction in Adulthood of Prematurely Born (LUNAPRE)

Condition:   Premature Birth- and BPD-related Obstructive Lung Disease
Intervention:  
Sponsors:   Karolinska Institutet;   Swedish Heart Lung Foundation;   The Swedish Research Council;   Stockholm County Council, Sweden;   Stockholm South General Hospital;   University of California, San Francisco;   Kyoto University;   Göteborg University;   University of Oulu
Recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days